Disease Landscape and Forecast Insights

Recent launches of trastuzumab biosimilars (Celltrion/Mundipharma’s Herzuma, Samsung Bioepis/Merck & Co.’s Ontruzant, Amgen/Allergan’s Kanjinti) have expanded the biosimilar sector of the…

The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…

Immune biologics including TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products and therefore offer a great opportunity for biosimilars developers. The…

MARKET OUTLOOK Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second- and…

MARKET OUTLOOK Chemotherapy has remained the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors,…

Market Outlook The currently available pharmacological treatments for opioid addiction fall into one of two categories: opioid receptor agonists (i.e., methadone, buprenorphine, and…

Hormone receptor (HR)-positive/HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status,…

Although ESA biosimilars entered the European market a decade ago, their uptake varies from country to country, as well as by drug and manufacturer. While European nephrologists have been able to…

MARKET OUTLOOK SLE is an autoimmune disease that can manifest in many different organs, including the kidneys. Renal inflammation associated with SLE, also known as lupus nephritis, is among the…

MARKET OUTLOOK SLE is an autoimmune disease characterized by varied symptoms ranging from general fatigue to serious organ manifestations. Options available to treat SLE are limited, with…

Stage of disease, resectability of the primary tumor, and BRAF-mutation status (in the unresectable or metastatic setting) are key parameters that influence the treatment paradigm of malignant…

Market OutlookHyperaldosteronism is characterized by the excessive release of aldosterone hormone into the blood and the resulting rise in blood pressure. This disorder is a common cause of…